TY - JOUR
T1 - Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis
T2 - Prevalence and Clinical Associations in Two US Cohorts
AU - Hanif, Iqtidar
AU - Assassi, Shervin
AU - Mayes, Maureen D.
AU - McMahan, Zsuzsanna H.
AU - Zhang, Meng
AU - Charles, Julio
AU - VanBuren, John M.
AU - Alvey, Jessica S.
AU - Ghaffari, Kimia
AU - Bernstein, Elana J.
AU - Castelino, Flavia V.
AU - Chung, Lorinda
AU - Evnin, Luke
AU - Frech, Tracy M.
AU - Gordon, Jessica K.
AU - Hant, Faye N.
AU - Hummers, Laura K.
AU - Khanna, Dinesh
AU - Lakin, Kimberly S.
AU - Lebiedz-Odrobina, Dorota
AU - Luo, Yiming
AU - Makol, Ashima
AU - Molitor, Jerry A.
AU - Moore, Duncan F.
AU - Richardson, Carrie
AU - Sandorfi, Nora
AU - Shah, Ami A.
AU - Shah, Ankoor
AU - Shanmugam, Victoria K.
AU - Steen, Virginia D.
AU - Volkmann, Elizabeth R.
AU - Zahn, Carleigh
AU - Skaug, Brian
N1 - Publisher Copyright:
© 2025 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2025/11
Y1 - 2025/11
N2 - Objective: Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts. Methods: All patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non-RP symptom. Results: In GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non-RP initial symptom, most commonly puffy fingers/hands. Black patients had a non-RP symptom before RP more commonly than patients in other race and ethnicity categories. Non-RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity. Conclusion: In two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the “warning sign” of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc-associated autoantibodies, including RNA polymerase III.
AB - Objective: Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts. Methods: All patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non-RP symptom. Results: In GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non-RP initial symptom, most commonly puffy fingers/hands. Black patients had a non-RP symptom before RP more commonly than patients in other race and ethnicity categories. Non-RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity. Conclusion: In two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the “warning sign” of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc-associated autoantibodies, including RNA polymerase III.
UR - https://www.scopus.com/pages/publications/105011349224
UR - https://www.scopus.com/pages/publications/105011349224#tab=citedBy
U2 - 10.1002/art.43237
DO - 10.1002/art.43237
M3 - Article
C2 - 40386907
AN - SCOPUS:105011349224
SN - 2326-5191
VL - 77
SP - 1585
EP - 1595
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 11
ER -